Synthesis and biological evaluation of sulfonylurea and thiourea derivatives substituted with benzenesulfonamide groups as potential hypoglycemic agents

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 6, 2009, Pages 1740-1744

  Zhang, Hui bin ^a   Zhang, Ya an ^a   Wu, Guan zhong ^a   Zhou, Jin pei ^a   Huang, Wen long ^a   Hu, Xiao wen ^b  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Diabetic complications; Hypoglycemic activity; Sulfonylurea derivatives; Synthesis

Indexed keywords

ADRENALIN; ANTIDIABETIC AGENT; BENZENESULFONAMIDE DERIVATIVE; COLLAGEN; DALTROBAN; GLIMEPIRIDE; INSULIN; SULFONYLUREA; SULOTROBAN; TERUTROBAN; THIOUREA DERIVATIVE;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFECT; DRUG HALF LIFE; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; EXPERIMENTAL MODEL; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HYPOGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN RELEASE; KIDNEY DISEASE; MOUSE; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PANCREAS ISLET CELL; SUBSTITUTION REACTION;

ADIPOCYTES; ANIMALS; BIOLOGICAL TRANSPORT; CHEMISTRY, PHARMACEUTICAL; DIABETES MELLITUS; DRUG DESIGN; GLUCOSE; HYPOGLYCEMIC AGENTS; ISLETS OF LANGERHANS; MODELS, BIOLOGICAL; MODELS, CHEMICAL; RATS; SULFONAMIDES; SULFONYLUREA COMPOUNDS; THIOUREA;

MUS; RATTUS;

EID: 61349174765     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.01.082     Document Type: Article

References (33)

1. Davis S.N., and Thompson C.J. N. Engl. J. Med. 329 (1993) 977
2. Laakso M. Ann. Intern. Med. 124 (1996) 127
3. Keane W.F., and Brenner B.M. Kidney Int. 63 (2003) 1499
4. Andrew N. Diabetes Obes. Metab. 5 (2003) S11
5. Brownlee M. Nature 414 (2001) 1618
6. Huo Y., Schober A., Forlow S.B., et al. Nat. Med. 9 (2003) 61
7. Ruggeri Z.M. Nat. Med. 8 (2002) 1227
8. Kobayashi T., Tahara Y., Matsumoto M., Iguchi M., Sano H., Murayama T., Arai H., Oida H., Yurugi-Kobayashi T., Yamashita J.K., Katagiri H., Majima M., Yokode M., Kita T., and Narumiya S. J. Clin. Invest. 114 (2004) 784
9. Egan K.M., Wang M., Lucitt M.B., Zukas A.M., Puré E., Lawson J.A., and FitzGerald G.A. Circulation 11 (2005) 334
10. Hishinuma T., Tsukamoto H., Suzuki K., and Mizugaki M. Prostaglandins Leukot. Essent. Fatty Acids 65 (2001) 191
11. Craven P.A., Melhem M.F., and DeRubertis F.R. Kidney Int. 42 (1992) 937
12. Matsuo Y., Takagawa I., Koshida H., Kawabata T., Nakamura M., Ida T., Zhou L., and Marumo F. Pharmacology 50 (1995) 1
13. Xu S., Jiang B., Maitland K.A., and Bayat H. Diabetes 55 (2006) 110
14. Brownlee M. Diabetes 54 (2005) 1615
15. Cimetière B., Dubuffet T., Muller O., et al. Bioorg. Med. Chem. Lett. 8 (1998) 1375
16. Audoly L., Rocca B., Fabre J.E., Koller B.H., Thomas D., Loeb A.L., Coffman T.M., and FitzGerald G.A. Circulation 101 (2000) 2833
17. Worth N.F., Berry C.L., Thomas A.C., and Campbell J.H. Atherosclerosis 183 (2005) 65
18. Viles-Gonzalez J.F., Fuster V., Roberto C., Carolina V., Randolph H., Stefano C., Anand S.X., and Badimon J.J. Eur. Heart J. 26 (2005) 1557
19. Cayatte A.J., Du Y., Oliver-Krasinski J., Lavielle G., Verbeuren T.J., and Cohen R.A. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 1724
20. Zuccollo A., Shi C., Mastroiann R., Maitland-Toolan K.A., Weisbrod R.M., Zang M., Xu S., Jiang B., Oliver-Krasinski J.M., Cayatte A.J., Corda S., Lavielle G., Verbeuren T.J., and Cohen R.A. Circulation 112 (2005) 3001
21. Šebeková K., Eifert T., Klassen A., Heidland A., and Amann K. Diabetes 56 (2007) 968
22. Choi S.W., Benzie F.F., Ma S.W., Strain J.J., and Hannigan B.M. Free Radical Biol. Med. 44 (2008) 1217
23. Smith III E.F., and McDonald J. Pharmacology 36 (1988) 340
24. Englert H.C., Gerlanch U., and Goegelein H. J. Med. Chem. 44 (2001) 1085
25. 2: C 47.31, H 5.05, N 7.52; found: C 47.20, H 5.04, N 7.65.
26. The pancreatic tissue was removed from rats and digested with collagenase I for 5-8 min at 38 °C for 4-5 times. Dispersed pancreatic cells were washed with Hanks liquid (containing 10% fetal bovine serum). After centrifugation, the isolated cells were cultured in RPMI 1640 medium with the addition of 10% fetal bovine serum. Fibroblasts were taken out with iodoacetic acid incubated for 48 h. Final incubation were carried out for 6 h at 37 °C with glucose (25 mmol/L), test and standard compounds at different concentrations. The insulin concentration in 1640 medium was measured by radioimmunoassay method.
27. Jerrold M.O. Biochem. J. 172 (1978) 137
28. 3H was measured by liquid scintillation counting.
29. Fasted C57BL/6 J mice were dosed daily by oral gavage for 3 days. Treatments were compound 10 (20, 7, and 2.5 mg/kg), glimepiride (20 mg/kg) or vehicle (0.5% carboxymethylcellulose). On day 5, mice were weighed and the blood samples were collected from the cut tip of the tail vein at 0, 0.5, 1, 2, 4, and 6 h after dosing. Samples were assayed for glucose. Plasma glucose was measured using the glucose oxidase Trinder method.
30. -5 cells/μl by using PPP. By using ADP (5 μmol/L) and AA (200 μmol/L) as an aggregating inducer, respectively, platelet aggregation of Aspirin (ASP) solution or the test compound solution (final concentration of ASP and compound 10: 100, 10, 1, and 0.1 μmol/L) was assayed on a four-channel aggregometer (LBY-NJ2 type, Plysion Co., Ltd).
31. Chinese Kunming mice weighing about 30 g were grouped after overnight fasting (n = 11). Mice were dosed once daily by oral gavage for 7 days. Treatments were compound 10 (40, 20, and 10 mg/kg), ASP (60 mg/kg) or vehicle (0.5% carboxymethylcellulose). On day 7, at 1 h after dosing, 220 μg collagen and 8 μg epinephrine were injected intravenously for 20 s. The protective effects were calculated by measuring the incidence of death within 15 min of injection. Results are expressed as percent survival.
32. Shukla U.A., Chi E.M., and Lehr K.H. Ann. Pharmacother. 38 1 (2004) 30
33. Yamazaki H., and Tabata S. Arzneimittelforschung 43 12 (1993) 1317